Linezolid Krka (Linezolid)

Linezolid is an oxazolidinone antibiotic indicated for several serious bacterial infections.

• Skin and soft tissue infections: effective against Gram‑positive pathogens, including MRSA, to achieve clinical cure.
• Community‑acquired pneumonia: treats infection caused by susceptible Streptococcus pneumoniae and other organisms, improving respiratory outcomes.
• Hospital‑acquired (nosocomial) pneumonia: used for severe pneumonia caused by resistant Gram‑positive bacteria, facilitating bacterial eradication.
• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides an alternative therapy for MRSA when other agents are unsuitable.
• Vancomycin‑resistant Enterococcus (VRE) infections: offers activity against VRE strains, aiding infection control.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for translation. This action blocks the early stage of peptide chain assembly, resulting in a bacteriostatic effect against susceptible Gram‑positive organisms, including resistant strains such as MRSA and VRE. The binding site is distinct from those of other antibiotic classes, which reduces cross‑resistance and allows linezolid to retain activity where other agents fail.

Linezolid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools.
• Headache: transient cranial discomfort.
• Metallic taste: altered taste sensation.
• Myelosuppression (reversible): mild decrease in blood cell counts.
• Rash: skin irritation or mild eruption.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count.
• Peripheral neuropathy: nerve damage causing tingling or pain.
• Lactic acidosis: metabolic disturbance with high lactate.
• Serotonin syndrome: risk when combined with serotonergic agents.
• Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.

When prescribing linezolid, clinicians should consider several safety and handling precautions.

• Hematologic monitoring: perform baseline and periodic complete blood counts to detect myelosuppression.
• Renal and hepatic function: assess liver and kidney status, adjust use in severe impairment.
• Serotonergic drugs: avoid concomitant use with MAO inhibitors or SSRIs due to serotonin syndrome risk.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.
• Duration of therapy: limit to the shortest effective course to reduce toxicity.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Linezolid can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): concurrent use may precipitate serotonin syndrome.
• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Rifampicin: may reduce linezolid plasma concentrations, decreasing effectiveness.
• Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring.
• Anticonvulsants (e.g., carbamazepine): may lower linezolid levels, necessitating therapeutic monitoring.